Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
Clinical trial NCT02678299 · UNKNOWN
Trial details
- NCT number
- NCT02678299
- Sponsor
- University of Aarhus
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2022-02-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.